AURA BIOSCIENCES INC
AURANASDAQTrading Snapshot
- Day Range
- $7.23 – $7.37
- 52-Week Range
- $4.73 – $9.54
- Volume
- $4.80B
- Avg Volume
- $5.83B
- Shares Outstanding
- 103.4M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $104M
- Last Q Revenue
- $27M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.74
- Dividend Yield
- —
Why Investors Own AURA
- ✓High-growth profile — revenue up +22.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AURA BIOSCIENCES INC
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
- Sec Filing
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures higher, Deckers Outdoor shares fall after reporting Q1 results. Other stocks also down in pre-market trading. Photo via Shutterstock.
Why SAP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
SAP SE (NYSE: SAP) reported Q2 earnings of $1.85 per share, missing the consensus estimate. Revenue came in at $11.48 billion, just below expectations. SAP stock rose 5.9% in pre-market trading.